This webinar, Sarcoma & COVID-19: Your Questions Answered, produced by the Sarcoma Alliance, originally aired on May 2, 2020 and is available here for viewing. Hear advice from GIST Specialists on this health epidemic and how it affects GIST patients.
In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.
Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST).
The LRG is offering virtual opportunities for you to connect with others and have fun while supporting our goal of raising funds for our GIST Community!
Our Surgeon General, Dr. Jerome Adams, shares ways to create your own face covering in a few easy steps.
The LRG was featured in the MyPART Minute April edition, in the Advocacy Spotlight section, which detailed our mission, core values, and the story of our collaboration with the National Institutes of Health to create the annual NIH Pediatric and Wildtype GIST Clinic.
Conversations with the Life Raft Group will debuted 4/2/2020 at 1 pm. Our first featured guest was Norman J. Scherzer, the Executive Director of the Life Raft Group. With his background at the CDC as Assistant Commissioner of Health for NYC, Norman is an excellent resource for discussing strategies for coping with COVID-19.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
As the number of people who have fallen ill grows, the FDA announced approval if the use of two anti-malaria drugs for coronavirus.
